Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 57.1%Low 2 · 28.6%Moderate 1 · 14.3%High 0 · 0%

WHO progression score (level 7 or above) D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether sarilumab changes WHO progression score (level 7 or above) D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.1 [0.9, 1.33]
5 studies · 886 participants
Very low

All‐cause mortality D28 · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether sarilumab changes all‐cause mortality D28 compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.06 [0.86, 1.3]
9 studies · 3305 participants
Very low

All‐cause mortality D60 or more · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether sarilumab changes all‐cause mortality D60 or more compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.95 [0.84, 1.07]
6 studies · 3379 participants
Very low

Adverse events ( · people with mild/moderate/severe/critical COVID‐19

Sarilumab showed no clear difference in adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.12 [0.97, 1.28]
4 studies · 860 participants
Low

Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19

Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.09 [0.97, 1.21]
6 studies · 2936 participants
Low

Clinical improvement D28b · people with mild/moderate/severe/critical COVID‐19

Sarilumab showed no clear difference in clinical improvement D28b compared with standard care/placebo (moderate certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 0.99 [0.94, 1.05]
7 studies · 2425 participants
Moderate

Clinical improvement D60 or above · people with mild/moderate/severe/critical COVID‐19

It is very uncertain whether sarilumab changes clinical improvement D60 or moree compared with standard care/placebo (very low certainty).

1 finding from 1 review

Interleukin‐6 blocking agents for treating COVID‐19: a living systematic review 2023 · Cochrane Headline outcomes only
RR 1.22 [0.91, 1.63]
2 studies · 239 participants
Very low